Country: UNITED KINGDOM | UNITED STATESRegion: EUROPE, NORTH AMERICA | Type: Drug Launch | Keywords: #astrazeneca #az #azd1222 #coronavirus #covid19 #distribution #manufacturing #r&d #supplychain #vaccine
- AstraZeneca (AZ) concluded the first agreements for over 400 million doses of a COVID-19 vaccine and secured manufacturing capacity for a total of one billion doses so far, the company announced, with the first doses set to be delivered in September 2020
- AZ has collaborated with “a number of countries and multilateral organizations” to make the vaccine by the University of Oxford widely accessible to all
- The company formalized an agreement with the University of Oxford for the recombinant adenovirus vaccine, which is now known as AZD1222
CAMBRIDGE, United Kingdom – AstraZeneca (AZ) concluded the first agreements for over 400 million doses of a COVID-19 vaccine and secured manufacturing capacity for a total of one billion doses so far, the company announced.
The first doses will begin delivery in September 2020.
Going forward, the AZ aims to conclude more agreements supported by parallel supply chains to further expand capacity to ensure the coronavirus strain vaccine is accessible around the globe.
AZ has collaborated with “a number of countries and multilateral organizations” to make the vaccine by the University of Oxford widely accessible to all. The company joined forced with the UK’s government to support development of the Oxford vaccine.
Since, an agreement with the university for the recombinant adenovirus vaccine has been formalized. The vaccine is now known as AZD1222.
The company received over $1 billion in financial support from the United States’ Biomedical Advanced Research and Development Authority (BARDA) to develop, produce, and deliver the vaccine, commencing this fall. This program included a Phase 3 clinical trial with 30,000 participants and a pediatric trial.
On top of this, AZ is working with the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance, and the World Health Organization (WHO).
Pascal Soriot, Chief Executive Officer, AZ, said, “This pandemic is a global tragedy and it is a challenge for all of humanity. We need to defeat the virus together or it will continue to inflict huge personal suffering and leave long-lasting economic and social scars in every country around the world. We are so proud to be collaborating with Oxford University to turn their ground-breaking work into a medicine that can be produced on a global scale. We would like to thank the US and UK governments for their substantial support to accelerate the development and production of the vaccine. We will do everything in our power to make this vaccine quickly and widely available.”
Contact us with your questions and global pricing needs, and an expert will follow up shortly.